Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 7/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035436 | 0.84 | MEN1 (0.40) | CCR3DPP4DRD2HRH2HRH1 | |
| SCHEMBL7035876 | 0.79 | MEN1 (0.36) | DPP4HRH2HRH1 | |
| SCHEMBL7028488 | 0.79 | CD274 (0.61) | MKNK1MKNK2DRD3CCR3CD274 | |
| SCHEMBL6996059 | 0.78 | CCR3 (0.49) | MKNK1MKNK2DRD3CCR3CD274 | |
| SCHEMBL7035992 | 0.78 | KCNA5 (0.48) | HRH2HRH1 | |
| SCHEMBL6995153 | 0.77 | CCR3 (0.52) | CCR3 | |
| SCHEMBL7027153 | 0.76 | CCR3 (0.48) | MKNK1MKNK2DRD3CCR3CD274 | |
| SCHEMBL6997557 | 0.76 | CCR3 (0.48) | MKNK1MKNK2DRD3CCR3CD274 | |
| SCHEMBL6995882 | 0.76 | DRD3 (0.52) | MKNK1MKNK2DRD3CCR3CD274 | |
| SCHEMBL7033543 | 0.76 | CCR3 (0.48) | MKNK1MKNK2DRD3CCR3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | MKNK1 3025/4885MKNK2 3353/4885DRD3 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.